Abstract
International Journal of CancerEarly View LETTER TO THE EDITOR Reply to: Comments on “Adverse reactions associated with immune checkpoint inhibitors and bevacizumab: A pharmacovigilance analysis” Tianqi Gu, Tianqi Gu Department of Oncology, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, ChinaSearch for more papers by this authorAnqi Lin, Anqi Lin Department of Oncology, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, ChinaSearch for more papers by this authorHaitao Wang, Haitao Wang Thoracic Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USASearch for more papers by this authorJian Zhang, Corresponding Author Jian Zhang [email protected] Department of Oncology, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, China Correspondence Jian Zhang and Peng Luo, Department of Oncology, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, China. Email: [email protected] (J. Z.) and [email protected] (P. L.)Search for more papers by this authorPeng Luo, Corresponding Author Peng Luo [email protected] orcid.org/0000-0002-8215-2045 Department of Oncology, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, China Correspondence Jian Zhang and Peng Luo, Department of Oncology, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, China. Email: [email protected] (J. Z.) and [email protected] (P. L.)Search for more papers by this author Tianqi Gu, Tianqi Gu Department of Oncology, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, ChinaSearch for more papers by this authorAnqi Lin, Anqi Lin Department of Oncology, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, ChinaSearch for more papers by this authorHaitao Wang, Haitao Wang Thoracic Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USASearch for more papers by this authorJian Zhang, Corresponding Author Jian Zhang [email protected] Department of Oncology, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, China Correspondence Jian Zhang and Peng Luo, Department of Oncology, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, China. Email: [email protected] (J. Z.) and [email protected] (P. L.)Search for more papers by this authorPeng Luo, Corresponding Author Peng Luo [email protected] orcid.org/0000-0002-8215-2045 Department of Oncology, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, China Correspondence Jian Zhang and Peng Luo, Department of Oncology, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, China. Email: [email protected] (J. Z.) and [email protected] (P. L.)Search for more papers by this author First published: 09 March 2023 https://doi.org/10.1002/ijc.34497 Tianqi Gu and Anqi Lin are joint authors and they have contributed equally to this work and share first authorship. Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinkedInRedditWechat No abstract is available for this article. Early ViewOnline Version of Record before inclusion in an issue RelatedInformation
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
